11/19
08:20 am
itci
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]
11/19
08:00 am
itci
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Low
Report
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
11/7
08:00 am
itci
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Low
Report
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
11/6
09:02 am
itci
Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]
Low
Report
Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]
11/5
07:00 am
itci
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
Low
Report
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
11/4
09:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.
11/2
09:53 am
itci
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results [Yahoo! Finance]
Low
Report
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results [Yahoo! Finance]
11/1
08:53 am
itci
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
10/30
09:25 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $100.00 price target on the stock.
High
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $100.00 price target on the stock.
10/30
07:30 am
itci
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
High
Report
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
10/17
08:00 am
itci
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
Low
Report
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
10/11
12:46 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Morgan Stanley from $92.00 to $95.00. They now have an "overweight" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Morgan Stanley from $92.00 to $95.00. They now have an "overweight" rating on the stock.
10/4
11:36 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Royal Bank of Canada from $106.00 to $108.00. They now have an "outperform" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Royal Bank of Canada from $106.00 to $108.00. They now have an "outperform" rating on the stock.
9/23
08:00 am
itci
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
Low
Report
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
9/16
12:11 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $130.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $130.00 price target on the stock.
9/13
11:27 am
itci
Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone [Yahoo! Finance]
9/6
01:08 pm
itci
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]
9/6
07:56 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $92.00 price target on the stock, up previously from $68.00.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $92.00 price target on the stock, up previously from $68.00.
9/5
01:24 am
itci
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
8/28
08:00 am
itci
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
Low
Report
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences